Search

Your search keyword '"Cabrera, José-Rafael"' showing total 15 results
Start Over Author "Cabrera, José-Rafael"
15 results on '"Cabrera, José-Rafael"'

1. Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial

Author

Gómez-Barrena, Enrique, Rosset, Philippe, Gebhard, Florian, Hernigou, Philippe, Baldini, Nicola, Rouard, Helène, Sensebé, Luc, Gonzalo-Daganzo, Rosa M., Giordano, Rosaria, Padilla-Eguiluz, Norma, García-Rey, Eduardo, Cordero-Ampuero, José, Rubio-Suárez, Juan Carlos, Stanovici, Julien, Ehrnthaller, Christian, Huber-Lang, Markus, Flouzat-Lachaniette, Charles Henri, Chevallier, Nathalie, Donati, Davide Maria, Ciapetti, Gabriela, Fleury, Sandrine, Fernandez, Manuel-Nicolás, Cabrera, José-Rafael, Avendaño-Solá, Cristina, Montemurro, Tiziana, Panaitescu, Carmen, Veronesi, Elena, Rojewski, Markus Thomas, Lotfi, Ramin, Dominici, Massimo, Schrezenmeier, Hubert, and Layrolle, Pierre

Published
2019
Full Text
View/download PDF

4. Rituximab in the management of chronic immune thrombocytopenic purpura: an effective and safe therapeutic alternative in refractory patients

Author

Peñalver, Francisco Javier, Jiménez-Yuste, Victor, Almagro, Manuel, Alvarez-Larrán, Alberto, Rodríguez, Lluis, Casado, Marisol, Gallur, Laura, Giraldo, Pilar, Hernández, Roberto, Menor, Dolores, Rodríguez, Maria José, Caballero, Dolores, González, Raúl, Mayans, José, Millán, Isabel, and Cabrera, José Rafael

Published
2006
Full Text
View/download PDF

6. Early efficacy evaluation of mesenchymal stromal cells (MSC) combined to biomaterials to treat long bone non-unions

Author

Gómez-Barrena, Enrique, primary, Padilla-Eguiluz, Norma, additional, Rosset, Philippe, additional, Gebhard, Florian, additional, Hernigou, Philippe, additional, Baldini, Nicola, additional, Rouard, Helène, additional, Sensebé, Luc, additional, Gonzalo-Daganzo, Rosa-María, additional, Giordano, Rosaria, additional, García-Rey, Eduardo, additional, Cordero-Ampuero, José, additional, Rubio-Suárez, Juan Carlos, additional, García-Simón, Marta Dominguez, additional, Stanovici, Julien, additional, Ehrnthaller, Christian, additional, Huber-Lang, Markus, additional, Flouzat-Lachaniette, Charles Henri, additional, Chevallier, Nathalie, additional, Donati, Davide Maria, additional, Spazzoli, Benedetta, additional, Ciapetti, Gabriela, additional, Fleury, Sandrine, additional, Fernandez, Manuel-Nicolás, additional, Cabrera, José-Rafael, additional, Avendaño-Solá, Cristina, additional, Montemurro, Tiziana, additional, Panaitescu, Carmen, additional, Veronesi, Elena, additional, Rojewski, Markus Thomas, additional, Lotfi, Ramin, additional, Dominici, Massimo, additional, Schrezenmeier, Hubert, additional, and Layrolle, Pierre, additional

Published
2020
Full Text
View/download PDF

7. A paired trial comparing mononuclear cell collection in two machines for further inactivation through an inline or offline extracorporeal photopheresis procedure

Author

Bueno, José‐Luis, primary, Alonso, Rosalía, additional, Gonzalez‐Santillana, Clara, additional, Naya, Daniel, additional, Romera, Irene, additional, Alarcón, Ana, additional, Aguilar, Myriam, additional, Bautista, Guiomar, additional, Duarte, Rafael, additional, Ussetti, Piedad, additional, and Cabrera, José Rafael, additional

Published
2018
Full Text
View/download PDF

8. A paired trial comparing mononuclear cell collection in two machines for further inactivation through an inline or offline extracorporeal photopheresis procedure.

Author

Bueno, José‐Luis, Alonso, Rosalía, Gonzalez‐Santillana, Clara, Naya, Daniel, Romera, Irene, Alarcón, Ana, Aguilar, Myriam, Bautista, Guiomar, Duarte, Rafael, Ussetti, Piedad, Cabrera, José Rafael, Bueno, José-Luis, and Gonzalez-Santillana, Clara

Subjects
BLOOD transfusion, IMMUNOGLOBULINS, GRAFT versus host disease, CLINICAL trials, BLOOD diseases, BLOOD pressure, HEART beat, PHOTOCHEMOTHERAPY, TEMPERATURE, BRONCHIOLE diseases, MONONUCLEAR leukocytes
Abstract

Background: Extracorporeal photopheresis (ECP) is an effective treatment. However, protocols differ widely, and some questions, such as the number of cells to be collected or the number of ECP treatment days per treatment cycle, are still unsolved. The aim of this study was to compare a multistep (offline) (Spectra Optia and Macogenic G2) against an integrated (inline) ECP system (Therakos Cellex system) with respect to mononuclear cell (MNC) collection.Study Design and Methods: The number and quality parameters of the MNC products collected were evaluated together with some machine parameters, such as collection time. Comparisons were made through paired sample analysis with the t test.Results: Fourteen patients underwent 15 double-paired procedures using both ECP protocols. The average MNC collected in the multistep procedure was 77.4 × 108 , four times more than in the integrated procedure (18.5 × 108 ). MNC purity (84.4% vs. 63.8%) and enrichment (27.9 vs. 5.9) in the product collected were also higher in the multistep procedure. The whole ECP time was higher in the multistep than in the integrated procedure (272 vs. 106 min), but the calculated time to collect 25 × 108 MNCs in the multistep was shorter compared with the one-step procedure (77.8 vs. 172 min). All these differences between the two protocols were statistically significant.Conclusions: These two ECP protocols are different with respect to MNC collection and length of procedure. Some unresolved questions, such as the better MNC dose to inactivate or the number of consecutive days that ECP should be performed for optimal clinical efficacy, require further review. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

9. Paroxysmal nocturnal hemoglobinuria: a single S panish center's experience over the last 40 yr

Author

Muñoz‐Linares, Cristina, primary, Ojeda, Emilio, additional, Forés, Rafael, additional, Pastrana, Miguel, additional, Cabero, Martín, additional, Morillo, Daniel, additional, Bautista, Guiomar, additional, Baños, Isolina, additional, Monteserín, Carmen, additional, Bravo, Pilar, additional, Jaro, Esther, additional, Cedena, Teresa, additional, Steegmann, Juan Luis, additional, Villegas, Ana, additional, and Cabrera, José Rafael, additional

Published
2014
Full Text
View/download PDF

10. Graft-Failure After Allogeneic Stem Cell Transplantation. Outcome and Prognostic Factors in 80 Patients

Author

Ferrà, Christelle, primary, Sanz, Jaime, additional, Díaz-Pérez, Miguel-Angel, additional, Morgades, Mireia, additional, Gayoso, Jorge, additional, Cabrera, José-Rafael, additional, Villaescusa, María-Teresa, additional, Sanz, Guillermo, additional, Fernández-Avilés, Francesc, additional, Solano, Carlos, additional, Duarte, Rafael F., additional, Ortin, Miguel, additional, Heras, Inmaculada, additional, José-María, Moraleda, additional, De la Serna, Javier, additional, Cristina, Barrenetxea, additional, and Ribera, Josep-Maria, additional

Published
2011
Full Text
View/download PDF

11. Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients.

Author

Ferrà, Christelle, Sanz, Jaime, Díaz-Pérez, Miguel-Angel, Morgades, Mireia, Gayoso, Jorge, Cabrera, José-Rafael, Villaescusa, Teresa, Sampol, María-Antonia, Fernández-Avilés, Francesc, Solano, Carlos, Ortín, Miguel, Duarte, Rafael, Cuesta, Marian, Heras, Inmaculada, de la Serna, Javier, Moraleda, José-María, Barrenetxea, Cristina, González-Vicent, Marta, Sanz, Guillermo, and Ribera, Josep-Maria

Subjects
GRAFT rejection, GRAFT versus host disease, STEM cell transplantation, NEUTROPHILS, BONE marrow, PROGENITOR cells, CONFIDENCE intervals, HEMATOPOIETIC stem cells
Abstract

Strategies for reversing graft failure (GF) after allogeneic stem cell transplant (SCT) depend on the options available in each situation. GF was reported in 16 Spanish institutions from January 2006 to July 2011. Primary GF was defined as an absolute neutrophil count (ANC) > 0.5 × 109/L not reached by day + 28 after SCT from peripheral blood (PB) or bone marrow (BM) progenitors and by day + 42 after SCT from unrelated cord blood (UCB) progenitors. Secondary GF was defined as a recurrent ANC < 0.5 × 109/L. Eighty-nine patients with GF were reported, and 80 patients received a second SCT. The 5-year survival probability was 31% (95% confidence interval [CI]: 18-44%), and the incidences of non-relapse mortality and relapse estimated by competing risks were 47% (95% CI: 36-58%) and 21% (95% CI: 4-28%). The strategy adopted to treat GF was heterogeneous, and no approach could be unequivocally recommended for this situation. The prognosis of patients with GF was poor even after successful recovery from GF. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

12. Paroxysmal Nocturnal Hemoglobinuria and Magnetic Resonance Imaging

Author

Pastrana, Miguel, Muñoz-Linares, Cristina, Ojeda, Emilio, Fores, Rafael, Brea, Beatriz, Cabero, Martin, Morillo, Daniel, Bautista, Guiomar, Navarro, Belen, Krsnik, Isabel, de LaIglesia, Almudena, Gil, Santiago, Regidor, Carmen, Bueno, Jose Luis, Garcia-Marco, Jose A, and Cabrera, Jose Rafael

Published
2013
Full Text
View/download PDF

14. Use of Romiplostim to Facilitate Platelet Engraftment in Allogeneic Hematopoietic Transplantation

Author

Ojeda, Emilio, Garcia-Marco, Jose A., Navarro, Belen, DelaIglesia, Almudena, Fores, Rafael, Bautista, Guiomar, Krsnik, Isabel, Sanchez-Guerrero, Amelia, SanJuan, Isabel, Regidor, Carmen, Gil, Santiago, Gonzalo-Daganzo, Rosa, Martin-Donaire, Trinidad, Sanchez, Rocio, Bravo, Gracia, Claros, Nuria, Cabero, Martin, Beltran, Pilar, and Cabrera, Jose Rafael

Published
2011
Full Text
View/download PDF

15. Feasibility and safety of treating non-unions in tibia, femur and humerus with autologous, expanded, bone marrow-derived mesenchymal stromal cells associated with biphasic calcium phosphate biomaterials in a multicentric, non-comparative trial

Author

Nicola Baldini, Elena Veronesi, Nathalie Chevallier, Enrique Gómez-Barrena, Philippe Rosset, Pierre Layrolle, Philippe Hernigou, Cristina Avendaño-Solá, Gabriela Ciapetti, Sandrine Fleury, Massimo Dominici, Tiziana Montemurro, Rosaria Giordano, José Cordero-Ampuero, Jose Rafael Cabrera, M.N. Fernández, Hélène Rouard, Juan Carlos Rubio-Suárez, Ramin Lotfi, Markus Rojewski, Christian Ehrnthaller, Luc Sensebé, Hubert Schrezenmeier, Markus Huber-Lang, Florian Gebhard, Charles Henri Flouzat-Lachaniette, Norma G. Padilla-Eguiluz, Julien Stanovici, Davide Maria Donati, Carmen Panaitescu, Rosa Gonzalo-Daganzo, Eduardo García-Rey, Servicio de Cirugía Ortopédica y Traumatología [Madrid, Spain], Universidad Autonoma de Madrid (UAM)-Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina [Madrid, Spain], Service de Chirurgie Orthopédique et Traumatologique 2 [CHU Tours], Hôpital Trousseau (Tours)-Université Francois Rabelais [Tours]-Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Department of Traumatology, Hand-, Plastic-, and Reconstructive Surgery [Ulm, Germany], Universität Ulm - Ulm University [Ulm, Allemagne]-Center of Surgery [Ulm, Germany], Biomécanique cellulaire et respiratoire (BCR), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), Laboratory for Orthopaedic Pathophysiology and Regenerative Medicine [Bologna, Italy], University of Bologna-Department of Biomedical and Neuromotor Sciences [Bologna, Italy], Istituto Ortopedico Rizzoli [Bologna, Italy]-Istituto Ortopedico Rizzoli [Bologna, Italy], Etablissement Français du Sang Ile de France (EFS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], STROMALab, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Ecole Nationale Vétérinaire de Toulouse (ENVT), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement Français du Sang-Centre National de la Recherche Scientifique (CNRS), Servicio de Hematología [Madrid, Spain], Universidad Autonoma de Madrid (UAM)-Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], Cell Factory, Center for Cellular Therapy and Cryobiology [Milano, Italy], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Victor Babes University of Medicine and Pharmacy [Timisoara, Romania], Laboratory of Cellular Therapies [Modena, Italy], University - Hospital of Modena and Reggio Emilia [Modena, Italy]- Department of Medical and Surgical Sciences for Children & Adults [Modena, Italy], Institute for Clinical Transfusion Medicine and Immunogenetic Ulm [Ulm, Germany], Institut für Klinische Transfusionsmedizin und Immungenetik Ulm -IKT [Ulm, Germany], Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), EU-FP7-HEALTH-2009, REBORNE Project (GA: 241876)., Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina [Madrid, Spain]-Universidad Autonoma de Madrid (UAM), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)-Université Francois Rabelais [Tours]-Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Vétérinaire de Toulouse (ENVT), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Etablissement Français du Sang-Institut National de la Santé et de la Recherche Médicale (INSERM), Victor Babeş University of Medicine and Pharmacy (UMFT), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), UAM. Departamento de Cirugía, UAM. Departamento de Farmacología, UAM. Departamento de Medicina, Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université Francois Rabelais [Tours]-Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Gómez-Barrena, Enrique, Rosset, Philippe, Gebhard, Florian, Hernigou, Philippe, Baldini, Nicola, Rouard, Helène, Sensebé, Luc, Gonzalo-Daganzo, Rosa M., Giordano, Rosaria, Padilla-Eguiluz, Norma, García-Rey, Eduardo, Cordero-Ampuero, José, Rubio-Suárez, Juan Carlo, Stanovici, Julien, Ehrnthaller, Christian, Huber-Lang, Marku, Flouzat-Lachaniette, Charles Henri, Chevallier, Nathalie, Donati, Davide Maria, Ciapetti, Gabriela, Fleury, Sandrine, Fernandez, Manuel-Nicolá, Cabrera, José-Rafael, Avendaño-Solá, Cristina, Montemurro, Tiziana, Panaitescu, Carmen, Veronesi, Elena, Rojewski, Markus Thoma, Lotfi, Ramin, Dominici, Massimo, Schrezenmeier, Hubert, Layrolle, Pierre, Universidad Autónoma de Madrid (UAM)-Hospital Universitario La Paz-IdiPAZ and Facultad de Medicina [Madrid, Spain], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université Francois Rabelais [Tours], University of Bologna/Università di Bologna-Department of Biomedical and Neuromotor Sciences [Bologna, Italy], Universidad Autónoma de Madrid (UAM)-Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], Institut National de la Recherche Agronomique (INRA)-Université de Nantes (UN), and maurice, sandrine

Subjects
Calcium Phosphates, Biocompatible Materials, 02 engineering and technology, Bone tissue engineering, Fractures, Bone, Femur, media_common, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, 0303 health sciences, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, 021001 nanoscience & nanotechnology, 3. Good health, Clinical trial, medicine.anatomical_structure, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Mechanics of Materials, [SDV.IB]Life Sciences [q-bio]/Bioengineering, 0210 nano-technology, medicine.medical_specialty, Bioceramic, Medicina, Biophysics, Ceramics and Composite, Bioengineering, Mesenchymal Stem Cell Transplantation, Non-union, Transplantation, Autologous, Non union, Expanded autologous BM-hMSC, Biomaterials, 03 medical and health sciences, medicine, media_common.cataloged_instance, Humans, Humerus, Tibia, European union, [SDV.IB.BIO]Life Sciences [q-bio]/Bioengineering/Biomaterials, 030304 developmental biology, Cell Proliferation, [SDV.IB] Life Sciences [q-bio]/Bioengineering, business.industry, Mesenchymal stem cell, Mesenchymal Stem Cells, ATMP, Biomaterial, Surgery, [SDV.IB.BIO] Life Sciences [q-bio]/Bioengineering/Biomaterials, Biophysic, Fractures, Ununited, Ceramics and Composites, Feasibility Studies, Bone marrow, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background: ORTHO-1 is a European, multicentric, first in human clinical trial to prove safety and feasibility after surgical implantation of commercially available biphasic calcium phosphate bioceramic granules associated during surgery with autologous mesenchymal stromal cells expanded from bone marrow (BM-hMSC) under good manufacturing practices, in patients with long bone pseudarthrosis. Methods: Twenty-eight patients with femur, tibia or humerus diaphyseal or metaphyso-diaphyseal non-unions were recruited and surgically treated in France, Germany, Italy and Spain with 100 or 200 million BM-hMSC/mL associated with 5–10 cc of bioceramic granules. Patients were followed up during one year. The investigational advanced therapy medicinal product (ATMP) was expanded under the same protocol in all four countries, and approved by each National Competent Authority. Findings: With safety as primary end-point, no severe adverse event was reported as related to the BM-hMSC. With feasibility as secondary end-point, the participating production centres manufactured the BM-hMSC as planned. The ATMP combined to the bioceramic was surgically delivered to the non-unions, and 26/28 treated patients were found radiologically healed at one year (3 out of 4 cortices with bone bridging). Interpretation: Safety and feasibility were clinically proven for surgical implantation of expanded autologous BM-hMSC with bioceramic. Funding: EU-FP7-HEALTH-2009, REBORNE Project (GA: 241876)., The research leading to these results has received funding from the European Research Council under the European Union's Seventh Framework Programme (FP7/FP7-HEALTH-2009); REBORNE Project (GA: 241876)

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results